Horizon Pharma PLC (HZNP), Flamel Technologies S.A. (ADR) (FLML) & More: Why Should You Consider Following Broadfin Capital’s Investment Moves?

Broadfin Capital must have had positive expectations regarding AngioDynamics, Inc. (NASDAQ:ANGO) performance in the third quarter, since, during the second quarter, it had boosted its stake in the company by 44% to 3.61 million shares, which were worth $51.84 million. The bet paid off, as the stock brought a positive return of 22.1% during the third quarter. A total of 12 investors from our database held shares of AngioDynamics at the end of June, down by 14% over the quarter. Among the biggest shareholders of AngioDynamics, Inc. (NASDAQ:ANGO) was RGM Capital, which amassed a stake valued at $48.6 million. Royce & Associates, Renaissance Technologies, and D E Shaw also held valuable positions in the company.

The last stock we are going to examine in this article is Retrophin Inc (NASDAQ:RTRX), which returned 25.7% during the third quarter. In the second quarter, Broadfin had trimmed its exposure to the company by 10%, to 2.66 million shares, valued at $47.42 million. At the end of the second quarter, 18 funds followed by our team were bullish on this stock, down by 18% from the end of March. The largest stake in Retrophin Inc (NASDAQ:RTRX) was held by Scopia Capital, which reported holding $67.9 million worth of stock at the end of June. It was followed by Perceptive Advisors with a $58.4 million position. Other investors bullish on the company included Consonance Capital Management, and EcoR1 Capital.

Disclosure: None